The best peptides for women over 40 are FDA-approved drugs matched to a diagnosis: teriparatide and abaloparatide for postmenopausal osteoporosis (they cut new spine fractures by 65% to 86%), semaglutide and tirzepatide for obesity (15% to 21% average weight loss), and bremelanotide for low sexual desire before menopause.[2][3][5][6][7] Popular anti-aging injections such as epitalon and BPC-157 have no human outcome trials.[11][13]
The biggest health levers after 40 are still not peptides: strength training, bone and heart screening, and treating menopause symptoms well. This guide ranks peptides by evidence. For related topics, see our longevity peptides hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Teriparatide (Forteo) | FDA-approved for this use | New spine fractures 5% vs 14% on placebo[2] | Approved: postmenopausal osteoporosis[4] | Teriparatide |
| Abaloparatide (Tymlos) | FDA-approved for this use | Fewer new spine and non-spine fractures over 18 months[3] | Approved: postmenopausal osteoporosis | Abaloparatide |
| Semaglutide (Wegovy) | FDA-approved for this use | 14.9% average weight loss at 68 weeks[5] | Approved: obesity, heart risk | Semaglutide |
| Tirzepatide (Zepbound) | FDA-approved for this use | Up to 20.9% weight loss at 72 weeks[6] | Approved: obesity, sleep apnea | Tirzepatide |
| Bremelanotide (Vyleesi) | FDA-approved for this use | Small gains in desire vs placebo, premenopausal women[8] | Approved: premenopausal HSDD only[7] | PT-141 |
| Oxytocin (nasal) | Human RCTs | No better than placebo for sexual function[9] | Not approved for this use | Oxytocin |
| GHK-Cu, Matrixyl (topical) | Small human studies | Modest skin changes; few placebo-controlled studies[10] | Cosmetics, not drugs | GHK-Cu |
| Epitalon | Animal or lab only | Telomerase activity in cultured cells[11] | Not approved | Epitalon |
| BPC-157 | Animal or lab only | Rat tendon healing; tiny human case series[13] | Not approved | BPC-157 |
Results come from separate trials and are not head-to-head comparisons.
Start with standard care
Menopause symptoms. Hormone therapy remains the most effective treatment for hot flashes and also prevents bone loss. For healthy women under 60 or within 10 years of menopause, the Menopause Society says benefits generally outweigh risks.[1] No peptide replaces it. Our guide to peptides for menopause covers the newer non-hormonal options.
Screening. A bone density scan, blood pressure, cholesterol, blood sugar and cancer screenings matter more after 40 than any supplement or injection.
Bone: the strongest peptide evidence
Bone loss speeds up in the years around menopause. For women who already have osteoporosis and a high fracture risk, two peptide drugs build new bone rather than only slowing its breakdown:
- Teriparatide, a fragment of parathyroid hormone, cut new spine fractures from 14% on placebo to 5% at the approved dose, a 65% relative reduction.[2][4]
- Abaloparatide, a related peptide, reduced new spine and non-spine fractures over 18 months in 2,463 women and caused less high blood calcium than teriparatide.[3]
Both are daily injections, and both are followed by another bone drug to keep the gains.
Weight and metabolism
Many women gain weight and abdominal fat in midlife. For those with obesity, or overweight plus a weight-related condition, GLP-1-based peptides are the best-studied option: semaglutide produced 14.9% average weight loss in STEP 1 and tirzepatide up to 20.9% in SURMOUNT-1.[5][6] Muscle can be lost along with fat, so pairing these drugs with strength training and adequate protein matters.
Sexual desire
Bremelanotide (Vyleesi), the approved form of PT-141, is an as-needed injection for premenopausal women with acquired, generalized low sexual desire that causes distress.[7] In two phase 3 trials, it improved desire scores by a small margin over placebo, and nausea, flushing and headache were common.[8] It is not approved after menopause.
Oxytocin nasal spray is sometimes promoted for libido. In a randomized crossover trial in pre- and postmenopausal women, sexual function improved about equally on oxytocin and placebo.[9] Read our PT-141 vs Viagra comparison for more on desire treatments.
Skin: modest, mostly cosmetic
Topical peptides such as copper peptide (GHK-Cu) and Matrixyl are sold as cosmetics, not drugs. A 2019 systematic review found only 15 clinical studies; just 6 used a placebo and 5 were double-blinded.[10] That doesn’t mean they do nothing, but the effects are small and the studies are often run by ingredient makers. Compare them in GHK-Cu vs Matrixyl and copper peptides vs retinol.
Anti-aging injections: little to no human evidence
Epitalon is marketed for longevity based on cell and animal studies, such as telomerase activation in cultured human cells.[11] See our epitalon vs TA-65 and mitochondrial peptides research pages. BPC-157, sold for joints and gut health, has only a few small, uncontrolled human reports.[13] Several peptides once sold for anti-aging remain on FDA’s list of compounding substances with significant safety concerns, and products bought online are unregulated.[12]
Sleep and energy
Poor sleep is one of the most common complaints in the 40s and 50s, often driven by night sweats. Peptides such as DSIP are marketed for sleep, but the human evidence is weak; see our DSIP vs melatonin comparison. If hot flashes are waking you, treating them directly helps: in the OASIS 1 and 2 trials, elinzanetant, a non-hormonal pill that blocks receptors for brain peptides involved in hot flashes, also improved sleep disturbance scores compared with placebo at 12 weeks.[15] Fatigue can also signal thyroid disease, anemia or sleep apnea, so it is worth a medical check before reaching for any peptide.
What about growth hormone peptides?
Clinics often market sermorelin, CJC-1295 and ipamorelin to women in midlife for sleep, skin and fat loss. These peptides prompt the pituitary to release more growth hormone. The human data mostly measure hormone levels: CJC-1295, for example, raised GH and IGF-1 for days after one injection in healthy adults, but that study did not track fat, skin or sleep.[14] The brand-name sermorelin product was discontinued in 2008, and neither CJC-1295 nor ipamorelin is approved. Higher IGF-1 is not automatically better, and long-term safety in women has not been studied.
Questions to discuss with your clinician
- Am I a candidate for menopause hormone therapy, and what are my personal risks?
- Do I need a bone density scan, and would a bone-building drug help me?
- Do I meet the criteria for an approved weight-loss medicine?
- If my sexual desire has dropped, what could be causing it, and is bremelanotide an option before menopause?
